Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

BACKGROUND: Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad, Lin, Yan, Lin, Huang, Rahman, Zahra, Vallabhaneni, Priyanka, Mendiratta, Prateek, Pingpank, James F., Holtzman, Matthew P., Yusko, Erik C., Rytlewski, Julie A., Rao, Uma N. M., Ferris, Robert L., Kirkwood, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199801/
https://www.ncbi.nlm.nih.gov/pubmed/30352626
http://dx.doi.org/10.1186/s40425-018-0428-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199801/
https://www.ncbi.nlm.nih.gov/pubmed/30352626
http://dx.doi.org/10.1186/s40425-018-0428-5

Ejemplares similares